stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.15
0.12
−2.28%
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) Net margin
Regencell Bioscience Holdings Limited's net margin over the twelve months to 30 June 2023 was 0.00%. Over the past ten years it has ranged from 0.00% (fiscal 2026) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −2.45% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | 0.00% | 0.00 |
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2023 | 0.00% | 0.00 |
| Dec 2022 | 0.00% | 0.00 |
| Jun 2022 | 0.00% | 0.00 |
| Dec 2021 | 0.00% | — |
Against its own ten years
Low 0.00%
High 0.00%
Ten-year median
0.00%
Current reading's percentile
100
Net margin against peers
| Company | Net margin |
|---|---|
| PBH Prestige Consumer Healthcare Inc. compare | 13.3% |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited | 0.00% |
| XERS Xeris Biopharma Holdings, Inc. compare | −1.76% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −23.6% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −37.4% |
| TRLV Trulieve Cannabis Corp. compare | −41.2% |
| PRGO Perrigo Company plc compare | −43.3% |
| ALVO Alvotech compare | −101.1% |
| Drug Manufacturers Specialty & Generic industry median | −2.45% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue